(Redirected from Fibrates)
Jump to navigation Jump to search
Aluminium clofibrate

WikiDoc Resources for Fibrate


Most recent articles on Fibrate

Most cited articles on Fibrate

Review articles on Fibrate

Articles on Fibrate in N Eng J Med, Lancet, BMJ


Powerpoint slides on Fibrate

Images of Fibrate

Photos of Fibrate

Podcasts & MP3s on Fibrate

Videos on Fibrate

Evidence Based Medicine

Cochrane Collaboration on Fibrate

Bandolier on Fibrate

TRIP on Fibrate

Clinical Trials

Ongoing Trials on Fibrate at Clinical

Trial results on Fibrate

Clinical Trials on Fibrate at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fibrate

NICE Guidance on Fibrate


FDA on Fibrate

CDC on Fibrate


Books on Fibrate


Fibrate in the news

Be alerted to news on Fibrate

News trends on Fibrate


Blogs on Fibrate


Definitions of Fibrate

Patient Resources / Community

Patient resources on Fibrate

Discussion groups on Fibrate

Patient Handouts on Fibrate

Directions to Hospitals Treating Fibrate

Risk calculators and risk factors for Fibrate

Healthcare Provider Resources

Symptoms of Fibrate

Causes & Risk Factors for Fibrate

Diagnostic studies for Fibrate

Treatment of Fibrate

Continuing Medical Education (CME)

CME Programs on Fibrate


Fibrate en Espanol

Fibrate en Francais


Fibrate in the Marketplace

Patents on Fibrate

Experimental / Informatics

List of terms related to Fibrate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


In pharmacology, the fibrates are a class of amphipathic carboxylic acids. They are used for a range of metabolic disorders, mainly hypercholesterolemia (high cholesterol), and are therefore hypolipidemic agents.


Fibrates prescribed commonly are:

Fenofibric acid (Trilipix) is FDA approved for combination use with statin, in patients with mixed dyslipidemia.


Fibrates are used as accessory therapy in many forms of hypercholesterolemia, usually in combination with statins. Trials do support its use as monotherapy.

Although less effective in lowering LDL, fibrates improve HDL and triglyceride levels, and seem to improve insulin resistance when the dyslipidemia is associated with other features of Syndrome X (hypertension and diabetes mellitus type 2).


Different doses of fenofibrate are available in the markets. The standard adult dose is usually >100 mg/day. However, dose lowering is required for patients with renal insufficiency (creatinine clearance < 80). Clinical trials are required to prove the relative efficacy of the different doses of fibrates.

Side effects

  • Mild stomach upset
  • Clofibrate are no longer used because they were found to increase morbidity and mortality rates. Also, increased rates of malignancy in rodents have been found.
  • Fibrates are excreted via kidney. It can cause reversible increases in serum creatinine levels. Thus, reduction in doses are indicated in cases with increased serum creatinine levels. Gemfibrozil's excretion is independent of renal function, and can be used in patients with chronic kidney disease.



Although used clinically since the early 1970s, the mechanism of action of fibrates remained unelucidated until, in the 1990s, it was discovered that fibrates activate PPAR (peroxisome proliferator-activated receptors), especially PPARα.

The PPARs are a class of intracellular receptors that modulate carbohydrate, fat metabolism and adipose tissue differentiation.

Activation of PPARs causes transcription of a number of genes on the DNA that facilitate lipid metabolism.

Fibrates are structurally and pharmacologically related to the thiazolidinediones, a novel class of anti-diabetic drugs that also act on PPARs (more specifically PPARγ)

See also

Template:Lipid modifying agents


Template:WikiDoc Sources